Pharmaceutical giant Moderna said it anticipates initial regulatory approvals of its respiratory syncytial virus vaccine will come in the first half of 2024, according to its Q4 earnings update published Feb. 22.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
